Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative CCRT for Esophageal Squamous Cell Carcinoma
NCT04764227Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- May 2020
- Primary completion
- Mar 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, carboplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fudan University. Started May 2020; status: active, not recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04764227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04764227.